相关实验视频
Updated: Jul 21, 2025
10:02
A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
Published on: November 3, 2016
24.3K
通过新生儿查识别的患者的脊椎肌肉缩治疗-系统性审查
Karolina Aragon-Gawinska1, Charlotte Mouraux2, Tamara Dangouloff2
1Department of Neurology, Medical University of Warsaw, 02-097 Warsaw, Poland.
Genes
|July 29, 2023
概括
脊椎肌肉缩 (SMA) 的早期治疗是有效的,特别是有更多的SMN2副本. 新生儿查有助于识别患者及时进行干预,改善运动功能的结果.
科学领域:
- 神经学 神经学
- 遗传学 遗传学 是一个
- 儿科 儿科 儿科
背景情况:
- 脊柱肌肉缩 (SMA) 的疾病修饰性治疗方法在症状出现之前使用时具有很高的疗效.
- 这导致许多国家在新生儿中实施SMA查计划.
- 然而,通过查诊断的患者的预后不能直接从涉及症状前个体的试验中推断出来,因为可能发生早期疾病呈现.
研究的目的:
- 系统地审查和评估脊柱肌肉缩 (SMA) 早期治疗的结果.
- 评估SMN2基因拷贝数和初始神经状态对治疗疗效的影响.
- 提供有关SMA患者接受早期干预的预后的见解.
主要方法:
- 进行了相关科学文献的系统审查.
- 分析了来自18个出版物的数据.
- 到2023年1月发表的文章被纳入了审查.
主要成果:
- 在35名患者中,有3个SMN2副本在42天前接受治疗,34名患者在18个月后实现了自主行走.
- 在41名患有两个SMN2副本的症状前患者中,所有人都能独立坐着,31人实现了行走.
- 在两个SMN2副本的16名症状患者中,只有3人走路,但所有人都可以在没有支持的情况下坐着.
结论:
- 脊柱肌肉缩 (SMA) 的早期治疗结果受到SMN2基因拷贝数量的显著影响.
- 在治疗开始时患者的初始神经状态是决定治疗成功的关键因素.
- 这些发现强调了在SMA管理中及时诊断和干预的重要性.
更多相关视频
06:51Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
7.7K
07:02Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
Published on: May 11, 2018
13.5K
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
01:21Satellite Stem Cells and Muscular Dystrophy
2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K